Spermosens AB (SPERM.ST)
SEK 0.01
(-3.23%)
SEK 0.01
(-3.23%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 26.1 Million SEK | -21.84% |
| 2022 | 33.39 Million SEK | 30.06% |
| 2021 | 25.67 Million SEK | 158.39% |
| 2020 | 9.93 Million SEK | 224.45% |
| 2019 | 3.06 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 27.3 Million SEK | 14.62% |
| 2024 Q3 | 24.99 Million SEK | -8.45% |
| 2024 Q1 | 23.82 Million SEK | -8.75% |
| 2023 Q4 | 26.1 Million SEK | -48.77% |
| 2023 FY | 26.1 Million SEK | -21.84% |
| 2023 Q3 | 50.95 Million SEK | 12.19% |
| 2023 Q2 | 45.42 Million SEK | -6.31% |
| 2023 Q1 | 48.47 Million SEK | 45.15% |
| 2022 Q1 | 24.84 Million SEK | -3.25% |
| 2022 FY | 33.39 Million SEK | 30.06% |
| 2022 Q4 | 33.39 Million SEK | -6.75% |
| 2022 Q3 | 35.81 Million SEK | -9.51% |
| 2022 Q2 | 39.57 Million SEK | 59.3% |
| 2021 Q4 | 25.67 Million SEK | -5.98% |
| 2021 Q1 | 9.15 Million SEK | -7.91% |
| 2021 Q3 | 27.31 Million SEK | -5.87% |
| 2021 Q2 | 29.01 Million SEK | 217.05% |
| 2021 FY | 25.67 Million SEK | 158.39% |
| 2020 Q4 | 9.93 Million SEK | 0.0% |
| 2020 FY | 9.93 Million SEK | 224.45% |
| 2019 FY | 3.06 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AroCell AB (publ) | 174.89 Million SEK | 85.074% |
| Devyser Diagnostics AB (publ) | 510.1 Million SEK | 94.882% |
| Immunovia AB (publ) | 98.68 Million SEK | 73.546% |
| Prostatype Genomics AB (publ) | 49.22 Million SEK | 46.965% |
| SenzaGen AB | 97.17 Million SEK | 73.136% |